Evidence index
Go to the
original guidance.
Sources checked October 5, 2026. Open current guidance when a question arises.
Sources and limits
Checked October 5, 2026. Federal sources provide general guidance; provider pages describe advertised terms. These sources do not assess an individual patient's situation.
- MedlinePlus — tirzepatide injection precautionsFederal patient drug information
- HRSA Poison Help — calling for expert guidanceFederal poison-response resource
- HRSA Poison Help — what you can doFederal emergency preparedness guidance
- FDA BeSafeRx — online pharmacy informationPharmacy verification and reporting resources
- CoreAge Rx — official treatment pagesProvider offer
- CoreAge Rx — tirzepatide offerProvider offer
- CoreAge Rx Help Center — Pricing & PlansProvider billing terms
- SuperHealthy Rx — current GLP-1 offerProvider offer
- Likeness Rx — GLP-1 plans and billingProvider offer
- Ro Body — membership and medication costsProvider offer
- WeightWatchers — Med+ membership and medicationProvider offer
- LillyDirect — pharmacy access and independent care optionsManufacturer access program
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance
- FDA — compounding questions and answersRegulator guidance
- FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
- NIDDK — prescription medications for overweight and obesityFederal patient education